1
|
Shinozaki K, Kirinoki M, Atcharaphan W, Watanabe KI, Ohari Y, Suguta S, Ona KAL, Ushio N, Macalanda AMC, Suganuma K, Inoue N, Kawazu SI. Expression profile analysis of the transient receptor potential (TRPM) channel, a possible target of praziquantel in Schistosoma japonicum. Parasitol Int 2024; 99:102833. [PMID: 38061487 DOI: 10.1016/j.parint.2023.102833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2023] [Revised: 11/28/2023] [Accepted: 11/28/2023] [Indexed: 01/08/2024]
Abstract
The WHO considers schistosomiasis, which is controlled by the mass administration of the drug praziquantel (PZQ), to be a neglected tropical disease. Despite its clinical use for over four decades, PZQ remains the only choice of chemotherapy against this disease. Regarding the previous studies that demonstrated that PZQ activates the transient receptor potential (TRP) channel in Schistosoma mansoni (Sm.TRPMPZQ), the expression profile of the ortholog of this channel gene (Smp_246790.5) in S. japonicum (EWB00_008853) (Sj.TRPMPZQ) was analyzed. The relative expression of this gene in various stages of the parasite lifecycle was analyzed by quantitative real-time reverse transcription-PCR (qRT-PCR), and the expression of Sj.TRPMPZQ was observed by immunohistochemical staining using anti-serum against the recombinant Sj.TRPMPZQ protein. qRT-PCR revealed the significantly lower mRNA expression in the snail stage in comparison to other stages (p < 0.01). The relative quantity of the Sj.TRPMPZQ expression for paired females, unpaired males, and eggs was 60%, 56%, and 68%, respectively, in comparison to paired males that showed the highest expression (p < 0.05). Interestingly, immunostaining demonstrated that Sj.TRPMPZQ is expressed in the parenchyma which contains muscle cells, neuronal cells and tegument cells in adult worms. This may support the two major effects of PZQ-worm paralysis and tegument disruption-induced by channel activation. Moreover, the channel was expressed in both the eggshell and the miracidia inside, but could not be observed in sporocyst. These results suggest that the expression of Sj.TRPMPQZ corresponds to the known sensitivity of S. japonicum to PZQ.
Collapse
Affiliation(s)
- Kaho Shinozaki
- National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Hokkaido 080-8555, Japan
| | - Masashi Kirinoki
- Laboratory of Tropical Medicine and Parasitology, Dokkyo Medical University, Tochigi 321-0293, Japan
| | - Wanlop Atcharaphan
- National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Hokkaido 080-8555, Japan
| | - Ken-Ichi Watanabe
- Laboratory of Veterinary Pathology, Obihiro University of Agriculture and Veterinary Medicine, Hokkaido 080-8555, Japan
| | - Yuma Ohari
- Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Hokkaido 001-0020, Japan
| | - Saki Suguta
- National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Hokkaido 080-8555, Japan
| | - Kevin Austin L Ona
- College of Medicine, University of the Philippines Manila, 1000 Manila, Philippines
| | - Nanako Ushio
- National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Hokkaido 080-8555, Japan
| | - Adrian Miki C Macalanda
- National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Hokkaido 080-8555, Japan; College of Veterinary Medicine and Biomedical Sciences, Cavite State University, Indang 4122, Cavite, Philippines
| | - Keisuke Suganuma
- National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Hokkaido 080-8555, Japan
| | - Noboru Inoue
- National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Hokkaido 080-8555, Japan
| | - Shin-Ichiro Kawazu
- National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Hokkaido 080-8555, Japan.
| |
Collapse
|
2
|
Villamizar-Monsalve MA, López-Abán J, Vicente B, Peláez R, Muro A. Current drug strategies for the treatment and control of schistosomiasis. Expert Opin Pharmacother 2024:1-12. [PMID: 38511392 DOI: 10.1080/14656566.2024.2333372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2024] [Accepted: 03/18/2024] [Indexed: 03/22/2024]
Abstract
INTRODUCTION Schistosomiasis, one of the current Neglected Tropical Diseases (NTDs) affects over 230 million people globally, with nearly 700 million at risk in more than 74 countries. Praziquantel (PZQ) has served as the primary treatment for the past four decades; however, its effectiveness is limited as it solely eliminates adult worms. In regions where infections are frequent, PZQ exhibits only temporary efficacy and has restricted potential to disrupt the prolonged transmission of the disease. AREAS COVERED A comprehensive exploration using the PubMed database was conducted to review current pharmacotherapy approaches for schistosomiasis. This review also encompasses recent research findings related to potential novel therapeutics and the repurposing of existing drugs. EXPERT OPINION Current schistosoma treatment strategies, primarily relying on PZQ, face challenges like temporary effectiveness and limited impact on disease transmission. Drug repurposing, due to economic constraints, is decisive for NTDs. Despite PZQ's efficacy, its failure to prevent reinfection highlights the need for complementary strategies, especially in regions with persistent environmental foci. Integrating therapies against diverse schistosome stages boosts efficacy and impedes resistance. Uncovering novel agents is essential to address resistance concerns in tackling this neglected tropical disease. Integrated strategies present a comprehensive approach to navigate the complex challenges.
Collapse
Affiliation(s)
- María Alejandra Villamizar-Monsalve
- Infectious and Tropical Diseases Research Group (e-INTRO), Biomedical Research Institute of Salamanca Research Centre for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Salamanca, Spain
| | - Julio López-Abán
- Infectious and Tropical Diseases Research Group (e-INTRO), Biomedical Research Institute of Salamanca Research Centre for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Salamanca, Spain
| | - Belén Vicente
- Infectious and Tropical Diseases Research Group (e-INTRO), Biomedical Research Institute of Salamanca Research Centre for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Salamanca, Spain
| | - Rafael Peláez
- Organic and Pharmaceutical Chemistry Department, Biomedical Research Institute of Salamanca Research Centre for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Salamanca, Spain
| | - Antonio Muro
- Infectious and Tropical Diseases Research Group (e-INTRO), Biomedical Research Institute of Salamanca Research Centre for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Salamanca, Spain
| |
Collapse
|
3
|
Waechtler A, Cezanne B, Maillard D, Sun R, Wang S, Wang J, Harder A. Praziquantel - 50 Years of Research. ChemMedChem 2023; 18:e202300154. [PMID: 37009677 DOI: 10.1002/cmdc.202300154] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2023] [Revised: 03/31/2023] [Accepted: 03/31/2023] [Indexed: 04/04/2023]
Abstract
Investigations on praziquantel (PZQ) started fifty years ago by a cooperation between Bayer AG and Merck KGaA. Until today PZQ is the drug of choice for schistosomiasis in human medicine and used in many combinations with antinematode drugs in veterinary medicine. The Sm.TRPMPZQ , a Ca2+ -permeable transient receptor potential (TRP) channel, has been discovered as primary target of PZQ during the last decade. Furthermore, there is a short overview of routes of large-scale synthesis of racemic and pure (R)-PZQ. Until now racemic PZQ is used in veterinary and human medicine. In 2012 the Pediatric Praziquantel Consortium started PZQ chemistry and process development of pure (R)-PZQ for human application. It is hoped that (R)-PZQ will become available for pediatric use soon. The knowledge of the binding pocket of PZQ in Sm.TRPMPZQ allows to design synthesis of PZQ-derivatives of the next generation for a target-site directed screening. A similar screening should also be started for Fasciola hepatica TRPMPZQ .
Collapse
Affiliation(s)
- Andreas Waechtler
- Central Process Development Department (EL-OTS) Merck KGaA, Frankfurter Str. 250, 64293, Darmstadt, Germany
| | - Bertram Cezanne
- Central Process Development Department (EL-OTS) Merck KGaA, Frankfurter Str. 250, 64293, Darmstadt, Germany
| | - David Maillard
- Central Process Development Department (EL-OTS) Merck KGaA, Frankfurter Str. 250, 64293, Darmstadt, Germany
| | - Rui Sun
- R&D Department, Valiant Pharmaceutical Co. Ltd., Taiyuan Road No. 60, YEDA, Yantai, Shandong, 264006, China
| | - Shaofang Wang
- Technical Department, Valiant Corporation Ltd., Wuzhishan Road No. 11, YEDA, Yantai, Shandong, 264006, China
| | - Jihua Wang
- Technical Department, Valiant Corporation Ltd., Wuzhishan Road No. 11, YEDA, Yantai, Shandong, 264006, China
| | - Achim Harder
- Department WE Biology, Institute of Biology, Heinrich-Heine University Düsseldorf, Universitätsstraße 1, 40225, Düsseldorf, Germany
| |
Collapse
|
4
|
Bayoumi AMA, Ismail MAM, Mahmoud SS, Soliman ASA, Mousa AMA, Yousof HASA. The potential curative and hepatoprotective effects of platelet rich plasma on liver fibrosis in Schistosoma mansoni experimentally infected mice. J Parasit Dis 2023; 47:349-362. [PMID: 37193508 PMCID: PMC10182195 DOI: 10.1007/s12639-023-01576-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2023] [Accepted: 03/03/2023] [Indexed: 04/05/2023] Open
Abstract
Trapped Schistosoma mansoni eggs trigger fibrotic liver disease that can continue to liver cirrhosis and failure. This work evaluates the outcome of platelet rich plasma (PRP) on S. mansoni-induced liver fibrosis by intraperitoneal (IP) and intrahepatic (IH) routes with/without Praziquantel (PZQ) treatment. Swiss albino mice (n = 162) were divided into non-infected (n = 66) and infected (n = 96) groups, then subdivided into non-treated and treated subgroups with PRP(IP), PRP(IH) 6th and 10th weeks post-infection, PZQ, PZQ + PRP(IP) and PZQ + PRP(IH) 6th and 10th weeks post-infection. Effects of treatments were evaluated by parasitological, histopathological and Immunohistochemical assessments. In the early assessment (12th week post-infection) of infected-treated groups, the mean granuloma number showed significant reduction in groups treated with PZQ + PRP (IH) 10th week, PRP (IP), PZQ + PRP (IP) and PZQ + PRP (IH) 6th week (33.33%, 33%, 27.77% and 27.22%, respectively). Furthermore, the mean granuloma diameter showed significant reduction in groups treated with PRP (IH) 10th week and PZQ + PRP (IP) (24.17% and 15.5%, respectively). Also, the fibrotic index showed significant reduction in groups treated with PZQ + PRP (IP), PRP (IP) and PZQ + PRP (IH) 6th week (48.18%, 46.81% and 41.36%, respectively). Transforming growth factor β1(TGF-β1) expression was in correlation with parasitological and histopathological results. Diminished TGF-β1 expression was mostly in infected groups treated with PZQ + PRP (IP), PZQ + PRP (IH) 6th week and PRP (IP) (88.63%, 88.63% and 77.27%, respectively). In the late assessment (14th week post-infection) of infected treated groups, TGF-β1expression was reduced in groups treated with PZQ, PRP (IH) 10th weeks, PRP (IP) (83.33%, 66.66%, 33.33% respectively). PRP showed promising anti-fibrotic effects on S. mansoni-induced liver fibrosis.
Collapse
Affiliation(s)
- Angham M. A. Bayoumi
- Medical Parasitology Department, Faculty of Medicine, Damietta University, Damietta, Egypt
| | - Mousa A. M. Ismail
- Medical Parasitology Department, Kasr Al-Ainy Faculty of Medicine, Cairo University, Kasr Al-Ainy St, Cairo, 11562 Egypt
| | - Soheir S. Mahmoud
- Parasitology Department, Theodor Bilharz Research Institute, Imbaba, Giza, Egypt
| | | | - Amr M. A. Mousa
- Pathology Department, Faculty of Medicine, October 6 University, 6th of October City, Egypt
| | - Hebat-Allah S. A. Yousof
- Medical Parasitology Department, Kasr Al-Ainy Faculty of Medicine, Cairo University, Kasr Al-Ainy St, Cairo, 11562 Egypt
| |
Collapse
|
5
|
Lacorcia M, Kugyelka R, Spechtenhauser L, Prodjinotho UF, Hamway Y, Spangenberg T, da Costa CP. Praziquantel Reduces Maternal Mortality and Offspring Morbidity by Enhancing Anti-Helminthic Immune Responses. Front Immunol 2022; 13:878029. [PMID: 35833137 PMCID: PMC9272909 DOI: 10.3389/fimmu.2022.878029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Accepted: 05/30/2022] [Indexed: 11/13/2022] Open
Abstract
Alongside the wide distribution throughout sub Saharan Africa of schistosomiasis, the morbidity associated with this chronic parasitic disease in endemic regions is often coupled with infection-driven immunomodulatory processes which modify inflammatory responses. Early life parasite exposure is theorized to drive immune tolerance towards cognate infection as well as bystander immune responses, beginning with in utero exposure to maternal infection. Considering that 40 million women of childbearing-age are at risk of infection worldwide, treatment with Praziquantel during pregnancy as currently recommended by WHO could have significant impact on disease outcomes in these populations. Here, we describe the effects of anthelminthic treatment on parasite-induced changes to fetomaternal cross talk in a murine model of maternal schistosomiasis. Praziquantel administration immediately prior to mating lead to clear re-awakening of maternal anti-parasite immune responses, with persistent maternal immune activation that included enhanced anti-schistosome cytokine responses. Clearance of parasites also improved capacity of dams to endure the additional pressure of pregnancy during infection. Maternal treatment also drove lasting functional alterations to immune system development of exposed offspring. Prenatal anthelminthic treatment skewed offspring immune responses towards parasite clearance and reduced morbidity during cognate infection. Maternal treatment also restored offspring protective IgE antibody responses directed against schistosome antigens, which were otherwise suppressed following exposure to untreated maternal infection. This was further associated with enhanced anti-schistosome cytokine responses from treatment-exposed offspring during infection. In the absence of cognate infection, exposed offspring further demonstrated imprinting across cellular populations. We provide further evidence that maternal treatment can restore a more normalized immune profile to such offspring exposed in utero to parasite infection, particularly in B cell populations, which may underlie improved responsiveness to cognate infection, and support the WHO recommendation of anthelminthic treatment during pregnancy.
Collapse
Affiliation(s)
- Matthew Lacorcia
- Technical University of Munich (TUM), School of Medicine, Institute for Med. Microbiology, Immunology and Hygiene, Munich, Germany
| | - Réka Kugyelka
- Technical University of Munich (TUM), School of Medicine, Institute for Med. Microbiology, Immunology and Hygiene, Munich, Germany
| | - Lorenz Spechtenhauser
- Technical University of Munich (TUM), School of Medicine, Institute for Med. Microbiology, Immunology and Hygiene, Munich, Germany.,Department of Biosciences, University of Salzburg, Salzburg, Austria
| | - Ulrich Fabien Prodjinotho
- Technical University of Munich (TUM), School of Medicine, Institute for Med. Microbiology, Immunology and Hygiene, Munich, Germany
| | - Youssef Hamway
- Technical University of Munich (TUM), School of Medicine, Institute for Med. Microbiology, Immunology and Hygiene, Munich, Germany
| | - Thomas Spangenberg
- Global Health Institute of Merck, Ares Trading S.A. (a subsidiary of Merck KGaA Darmstadt Germany), Eysins, Switzerland
| | - Clarissa Prazeres da Costa
- Technical University of Munich (TUM), School of Medicine, Institute for Med. Microbiology, Immunology and Hygiene, Munich, Germany
| |
Collapse
|